97298868 - C.

Information

  • Trademark
  • 97298868
  • Serial Number
    97298868
  • Filing Date
    March 07, 2022
    3 years ago
  • Transaction Date
    April 25, 2025
    8 months ago
  • Status Date
    April 23, 2025
    8 months ago
  • Published for Opposition Date
    January 24, 2023
    2 years ago
  • Location Date
    October 24, 2024
    a year ago
  • Status Code
    734
  • Employee Name
    ALTREE, NICK
  • Attorney Docket Number
    09367.0228
    Attorney Name
    B. Brett Heavner
    Law Office Assigned Location Code
    L70
  • Owners
Mark Drawing Code
3
Mark Identification
C.
Case File Statements
  • DM0000: The mark consists of stylized "C" with a circle between the opening.
  • GS0051: human pharmaceuticals for the treatment of pulmonary diseases, pulmonary conditions, bronchoconstrictive diseases, bronchoconstrictive conditions; infectious diseases, neurological diseases and conditions, neuromuscular diseases and conditions, musculoskeletal disorders, and diseases and conditions associated with skeletal muscle dysfunction, skeletal muscle wasting, skeletal muscle atrophy, skeletal muscle weakness, metabolic diseases and disorders, diabetes, hypertension, vascular diseases, and diseases and conditions associated with dysfunction of non-muscle myosin
  • CC0000: Color is not claimed as a feature of the mark.
Case File Event Statements
  • 3/10/2022 - 3 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 3/11/2022 - 3 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 3/12/2022 - 3 years ago
    3 - NOTICE OF DESIGN SEARCH CODE E-MAILED Type: MDSC
  • 12/17/2022 - 3 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 12/19/2022 - 3 years ago
    5 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 1/4/2023 - 3 years ago
    6 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 1/24/2023 - 2 years ago
    7 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 1/24/2023 - 2 years ago
    8 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 3/21/2023 - 2 years ago
    9 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 9/7/2023 - 2 years ago
    12 - SOU EXTENSION 1 GRANTED Type: EX1G
  • 9/7/2023 - 2 years ago
    10 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 9/7/2023 - 2 years ago
    11 - SOU EXTENSION 1 FILED Type: EXT1
  • 3/13/2024 - a year ago
    17 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 8/20/2024 - a year ago
    24 - DIVISIONAL REQUEST RECEIVED Type: DRRR
  • 9/9/2023 - 2 years ago
    13 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 3/12/2024 - a year ago
    14 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 3/12/2024 - a year ago
    15 - SOU EXTENSION 2 FILED Type: EXT2
  • 3/12/2024 - a year ago
    16 - SOU EXTENSION 2 GRANTED Type: EX2G
  • 8/20/2024 - a year ago
    18 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 8/20/2024 - a year ago
    21 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 8/20/2024 - a year ago
    19 - SOU EXTENSION 3 FILED Type: EXT3
  • 8/20/2024 - a year ago
    20 - SOU EXTENSION 3 GRANTED Type: EX3G
  • 8/20/2024 - a year ago
    22 - TEAS REQUEST TO DIVIDE RECEIVED Type: ERTD
  • 10/24/2024 - a year ago
    23 - CASE ASSIGNED TO INTENT TO USE PARALEGAL Type: AITU
  • 11/22/2024 - a year ago
    25 - DIVISIONAL PROCESSING COMPLETE Type: DPCC
  • 1/9/2025 - a year ago
    28 - SOU EXTENSION 4 FILED Type: EXT4
  • 3/17/2025 - 10 months ago
    29 - SOU EXTENSION 4 GRANTED Type: EX4G
  • 11/22/2024 - a year ago
    26 - CORRECTED NOA E-MAILED Type: NOAC
  • 1/9/2025 - a year ago
    27 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 3/18/2025 - 10 months ago
    30 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 4/1/2025 - 9 months ago
    32 - SOU EXTENSION 5 FILED Type: EXT5
  • 4/1/2025 - 9 months ago
    31 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 4/23/2025 - 8 months ago
    33 - SOU EXTENSION 5 GRANTED Type: EX5G
  • 4/24/2025 - 8 months ago
    34 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA